Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab + belrestotug vs pembrolizumab in PD-L1 high NSCLC
CTR20250284Phase 3Terminated
- Sponsor
- GSK
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dostarlimab, belrestotug, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Feb 2025; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250284.